CA2373039A1 - Composition neuroprotectrice et ses utilisations - Google Patents

Composition neuroprotectrice et ses utilisations Download PDF

Info

Publication number
CA2373039A1
CA2373039A1 CA002373039A CA2373039A CA2373039A1 CA 2373039 A1 CA2373039 A1 CA 2373039A1 CA 002373039 A CA002373039 A CA 002373039A CA 2373039 A CA2373039 A CA 2373039A CA 2373039 A1 CA2373039 A1 CA 2373039A1
Authority
CA
Canada
Prior art keywords
composition
antioxidant
pyruvate
vitamin
triad
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002373039A
Other languages
English (en)
Inventor
Eric De Grandpre
Mircea-Alexandru Mateescu
Joanne Paquin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gestilab Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002270795A external-priority patent/CA2270795A1/fr
Application filed by Individual filed Critical Individual
Priority to CA002373039A priority Critical patent/CA2373039A1/fr
Publication of CA2373039A1 publication Critical patent/CA2373039A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

L'invention concerne une composition neuroprotectrice, permettant de protéger des cellules neuronales contre les contraintes oxydatives, et des techniques de préparation et d'utilisation de cette composition. La composition neuroprotectrice comprend, en particulier, un mélange de pyruvate, d'antioxydant, et de lipide(s) tels que les acides gras. Elle peut être utilisée pour traiter un traumatisme cérébral, une ischémie cérébrale ou cérébrovasculaire, des maladies neurodégénératives, l'empoisonnement des cellules neuronales, la diminution des effets secondaires des médicaments, et pour préserver les greffes neuronales.
CA002373039A 1999-05-05 2000-05-05 Composition neuroprotectrice et ses utilisations Abandoned CA2373039A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002373039A CA2373039A1 (fr) 1999-05-05 2000-05-05 Composition neuroprotectrice et ses utilisations

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA2,270,795 1999-05-05
CA002270795A CA2270795A1 (fr) 1999-05-05 1999-05-05 Compositions neuroprotectrices et utilisations de ces compositions
PCT/CA2000/000523 WO2000067744A1 (fr) 1999-05-05 2000-05-05 Composition neuroprotectrice et ses utilisations
CA002373039A CA2373039A1 (fr) 1999-05-05 2000-05-05 Composition neuroprotectrice et ses utilisations

Publications (1)

Publication Number Publication Date
CA2373039A1 true CA2373039A1 (fr) 2000-11-16

Family

ID=25680926

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002373039A Abandoned CA2373039A1 (fr) 1999-05-05 2000-05-05 Composition neuroprotectrice et ses utilisations

Country Status (1)

Country Link
CA (1) CA2373039A1 (fr)

Similar Documents

Publication Publication Date Title
Gurel et al. Protective role of α-tocopherol and caffeic acid phenethyl ester on ischemia–reperfusion injury via nitric oxide and myeloperoxidase in rat kidneys
Martin The use of antioxidants in healing
Meerson et al. The role of lipid peroxidation in pathogenesis of ischemic damage and the antioxidant protection of the heart
US5591773A (en) Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters
US6858646B2 (en) Neuroprotective composition and uses thereof
Das et al. Nanoparticulated quercetin in combating age related cerebral oxidative injury
Anbarasi et al. Effect of bacoside A on membrane‐bound ATPases in the brain of rats exposed to cigarette smoke
Choi et al. Dietary flavonoids differentially reduce oxidized LDL-induced apoptosis in human endothelial cells: role of MAPK-and JAK/STAT-signaling
JP2002528480A (ja) グルタチオン産生を向上させる局所組成物
US20040063648A1 (en) Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
AU780159B2 (en) Ceruloplasmin and an antioxidant composition comprising the same and their uses as neuroprotective agent
WO2004075883A1 (fr) Utilisation de derives de curcumine ou de l'ester phenethylique d'acide cafeique dans la fabrication d'un medicament destine au traitement des troubles neurodegeneratifs
Santos et al. The iron chelator pyridoxal isonicotinoyl hydrazone inhibits mitochondrial lipid peroxidation induced by Fe (II)–citrate
CA2373039A1 (fr) Composition neuroprotectrice et ses utilisations
Cameron et al. Oxidative stress and abnormal lipid metabolism in diabetic complication
AU776964B2 (en) Cardioprotective composition and uses thereof
AU782065B2 (en) Cardioprotective composition comprising ceruloplasmin and uses thereof
CA2373058A1 (fr) Ceruloplasmine et composition antioxydante contenant cette substance, utilisations de ces dernieres en tant qu'agent neuroprotecteur
CA2373050A1 (fr) Composition cardioprotectrice et procedes d'utilisation
Radhiga et al. Potential beneficial effect of protocatechuic acid on hepatic markers, lipid peroxidation and antioxidant status against D-Galactosamine induced toxicity in rats
Gil-Mohapel Are Antioxidants Good Therapeutic Candidates for Huntington’s Disease
WO2023122827A1 (fr) Monoglycérides d'acides gras polyinsaturés, compositions, méthodes et utilisations associées
CA2373054A1 (fr) Composition cardioprotectrice contenant de la ceruloplasmine, utilisations de cette composition
MXPA00003200A (en) Inhibtion of lipoprotein oxidation

Legal Events

Date Code Title Description
FZDE Dead